Evaluation of WO2013076170: The use of a dihydroorotate dehydrogenase inhibitor for the treatment of psoriasis

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 10, 2013, Pages 1391-1394

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

Autoimmune disease; Dihydroorotate dehydrogenase; Nicotinic acid; Psoriasis

Indexed keywords

2 [(3,5 DIFLUORO 3' METHOXY 1,1' BIPHENYL 4 YL)AMINO]NICOTINIC ACID; BREQUINAR; DIHYDROOROTATE DEHYDROGENASE INHIBITOR; INFLIXIMAB; LAS 186323; LAS 187247; LEFLUNOMIDE; UNCLASSIFIED DRUG;

DRUG FORMULATION; DRUG POTENCY; DRUG SCREENING; HUMAN; IC 50; MULTIPLE SCLEROSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ANILINE COMPOUNDS; ANIMALS; ENZYME INHIBITORS; HUMANS; NICOTINIC ACIDS; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PATENTS AS TOPIC; PSORIASIS;

EID: 84884583854     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.831075     Document Type: Review

References (17)

1. Vyas VK, Ghate M. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Mini Rev Med Chem 2011;11(12):1039-55
2. Munier-Lehmann H, Vidalain PO, Tangy F, Janin YL. On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem 2013;56(8):3148-67
3. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93(3):198-208
4. Maroun J, Ruckdeschel J, Natale R, et al. Multicenter phase II study of brequinar sodium in patients with advanced lung cancer. Cancer Chemother Pharmacol 1993;32(1):64-6 (Pubitemid 23105009)
5. Kobayashi K, Nakashima A, Nagata H, et al. Anti-Arthritic effects of KF20444, a new immunosuppressive compound inhibiting dihydroorotate dehydrogenase, on rat collagen-induced arthritis. Inflamm Res 2001;50(1):24-31 (Pubitemid 32156115)
6. Chen J, Xia J, Axelsson B, et al. An N- (alkylcarbonyl)anthranilic acid derivative prolongs cardiac allograft survival synergistically with cyclosporine A in a high-responder rat model. Transpl Immunol 2010;23(4):180-4
7. Herrlinger KR, Diculescu M, Fellermann K, et al. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. J Crohns Colitis 2013;7(8):636-434SC AG, 4SC Announces topline results of phase IIb trial of vidofludimus in rheumatoid arthritis. 2011. Available from: http://www.dgap.de/link. php?template=4sc&anzahl=10& sprache=en&bis=20111231&von= 20110101&typ=corporate&id=676628
8. Almirall SA. Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors. WO2008077639; 2008
9. Almirall SA. Sodium salt of 5- cyclopropyl-2-{[2-(2,6- difluorophenyl) pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor. WO2010102824; 2010
10. Almirall SA. 2-[(3,5-Difluoro-3¢- methoxy-1,1¢-biphenyl-4-yl) amino] nicotinic Acid For The Treatment Of Psoriasis. WO2013076170; 2013
11. Godessart N, Andres M, Auli M, et al. Pharmacological profile of LAS186323, a novel non-hepatotoxic DHODH inhibitor for the oral treatment of multiple sclerosis and other autoimmune disorders. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2010
12. Erra M, Moreno I, Sanahuja J, et al. Biaryl analogues of teriflunomide as potent DHODH inhibitors. Bioorg Med Chem Lett 2011;21(24):7268-72
13. ASLAN Pharmaceutical. ASLAN announces a global license agreement with Almirall for LAS186323 in rheumatoid arthritis. 2012. Available from: http://www. Aslanpharma.com/download/Press% 20Release%20-%20Almirall-ASLAN% 20Licensing.pdf
14. Almirall SA. Process for manufacturing 2-[(3,5-difluoro-3¢-methoxy- 1,1¢- biphenyl-4-yl)amino]nicotinic acid. WO2011045059A1; 2011
15. Risek B, Pozzi A, Gilula NB. Modulation of gap junction expression during transient hyperplasia of rat epidermis. J Cell Science 1998;111(pt 10):1395-404 (Pubitemid 28274391)
16. Boyd AS. Leflunomide in dermatology. J Am Acad Dermatol 2012;66(4):673-9
17. Jones PBB, White DHN. Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis. Open Access Rheumatol Res Rev 2010;2:53-71